Skip to main content
. 2019 Jun 14;8(6):584. doi: 10.3390/cells8060584

Table 4.

Main clinico-pathologic characteristics of patients with HGSOC and number of mutated genes within the panel.

Characteristics >1 0 or 1 p 1 p 0 p
n = 7 n = 57 (>1 vs. 0 or 1) n = 45 (>1 vs. 1) n = 12 (>1 vs. 0)
Age
Median (range) 56.3 (48.5–72.1) 56.8 (31.0–81.4) 0.389 * 56.1(31.0–80.3) 0.318 * 58.9 (42.0–81.4) ns *
FIGO Stage a
 III 6 (85.7) 45 (78.9) 35 (77.8) 10 (83.3)
 IV 1 (14.3) 12 (21.1) 10 (22.2) 2 (16.7)
Tumor Grade
 G2 3 (42.9) 15 (26.3) 0.391 11 (24.4) 0.369 4 (33.3) 1.000
 G3 4 (57.1) 42 (73.7) 34 (75.6) 8 (66.7)
RD at PDS
 0 4 (57.1) 29 (50.9) 1.000 22 (48.9) 1.000 7 (58.3) 1.000
 <1 cm 3 (42.9) 28 (49.1) 23 (51.1) 5 (41.7)
Lymph Node involvement
 Negative 2 (28.6) 8 (14.0) 0.092 6 (13.3) 0.100 2 (16.7) 0.167
 Positive 1 (14.3) 33 (57.9) 26 (57.8) 7 (58.3)
 Unknown 4 (57.1) 16 (28.1) 13 (28.9) 3 (25.0)
Platinum sensitivity b
 Refractory 2 (28.6) 1 (1.8) 0.019 0 (0.0) 0.004 1 (8.3) 0.515
 Resistant 1 (14.3) 12 (21.0) 10 (22.2) 2 (16.7)
 Intermediate 2 (28.6) 17 (29.8) 15 (33.3) 2 (16.7)
 Sensitive 2 (28.6) 26 (45.6) 19 (42.2) 7 (58.3)

* Mann-Whitney test; a One patient with IIIB stage was included in IIIC (III vs. IV). a One patient with tumor grade G2-G3 was included in grade G3. b One patient was not evaluated due to loss at follow up. ns: not significant; FIGO: Fédération Internationale de Ginécologie et d’Obstetrique; RD: Residual Disease; PDS: primary debulking surgery. Comparisons were performed between the sub-group with 2 mutated genes (>1) and patients with: 1 mutated gene or not mutated (>1 vs. 0 or 1); patients with 1 mutated gene (>1 vs. 1); patients not mutated (>1 vs. 0). Fisher’s Exact test, Chi-squared test or Mann-Whitney test were used in the analyses; p values <0.05 were considered significant and were depicted in bold.